Paediatric Spasticity Treatment segmentation by type distinguishes five therapeutic modalities that together shape market dynamics. Botulinum toxin injections represent the largest share, driven by minimally invasive delivery, repeatability, and expanding indications across lower‑ and upper‑limb spasticity; they generate recurring revenue through frequent re‑dosing cycles. Phenol neurolysis, though less frequently employed, contributes a niche but high‑margin segment, primarily in older children where longer‑lasting denervation is clinically advantageous. Intrathecal baclofen therapy (ITB) forms a distinct high‑cost, device‑based category, accounting for substantial capital expenditure and ongoing pump refills, thus inflating total market value despite a smaller patient pool. Surgical interventions, including selective dorsal rhizotomy, add a one‑time procedural component that elevates overall spend through operative fees and post‑operative rehabilitation. Finally, adjunct physical‑therapy programs, while low‑cost per session, amplify market size through high utilization rates and integration with pharmacologic treatments. Collectively, these type sub‑segments define the revenue architecture of the Paediatric Spasticity Treatment market, each contributing a measurable proportion to the aggregate market size.
